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doi:10.1016/j.ejvs.2011.06.014Abstract A prospective study of 1969 patients with intermittent claudication receiving
placebo medication for a minimum of 1 year is reported. Patients were carefully monitored
and only four patients were lost to follow-up. Annual mortality was 4.3%. Thirty-six patients
developed a definite myocardial infarction, 27 a major stroke, 32 required a major amputation
and 111 required surgical or radiological intervention for deteriorating ischaemia of the leg.
The entry characteristics of the patients were analysed as a predictor of serious cardiovascular
events. The most sensitive predictors of total mortality were age, history of coronary heart
disease and an ankle/arm pressure ratio below 0.5. Of the laboratory measurements per-
formed only the initial white cell count was a significant predictor of myocardial infarction,
stroke and vascular deaths.
ª 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Introduction
The PACK (Prevention of Atherosclerotic Complications with
Ketanserin) trial is the largest, although not the longest,
carefully documented study of intermittent claudicants.1
The primary aim was to investigate in a double-blind
study of 3899 claudicants whether ketanserin, a serotonin
receptor antagonist,2 significantly altered the incidence of
serious cardiovascular events. The main conclusions in
terms of treatment effects have already been reported.1
This is a report of the short-term fate of the 1969 claudi-
cants who received a placebo. The authors of PACK hadlished in Eur J Vasc Endovasc
andy, Consultant Surgeon,
K.
lsevier Ltd on behalf of Europeanpreviously reviewed the existing literature on the fate of
the claudicant, and the vast majority of publications on
patients with ischaemic disease in the legs are concerned
with their surgical treatment.3 Very few previous studies
have looked at the fate of an unselected group of claudi-
cants in terms of mortality and cardiovascular morbidity.
Analysis of the 1969 patients in the placebo group of PACK
allows the accurate documentation of all the serious
complications of the claudicant and assessment of the
importance of various risk factors in relation to these
complications.Patients and Methods
1969 patients were randomised to the placebo group and all
further data refer solely to this group of patients. PatientsSociety for Vascular Surgery.
Table 1 Patient characteristics at randomisation.
Placebo
n Z 1969
Age, years (mean, S.D.) 63.2 (9.1)
Sex, male 1572 (80%)
MAPa (mmHg) (mean, S.D.) 107 (13)
MAP > 120 mmHg 275 (14%)
Hypertension (>160 and/or 95 mmHg
or receiving antihypertensive medication)
1113 (57%)
Ankle/arm ratio <0.05 316 (16%)
Ankle SBPb <70 mmHg 189 (10%)
Ankle/arm ratio >0.85 189 (10%)
Race, Caucasian 1922 (98%)
Regular smokers up to at least 6 months
previously
1396 (71%)
Diabetes 277 (14%)
Clinical evidence of previous disease
Coronary disease 539 (27%)
Cerebrovascular disease 168 (9%)
Arterial reconstruction for leg ischaemia 785 (40%)
Laboratory measurements
Haemoglobin (G%) 14.8 (S.D. 1.4)
White cell count (109/1) 7.7 (S.D. 2.3)
Cholesterol (mmol/1) 6.5 (S.D. 1.5)
Concomitant medication
None 537 (27%)
Digitalis 166 (8%)
Anti-arrhythmics 47 (2%)
Anti-anginals 411 (21%)
The Fate of the Claudicant S5were recruited using the same protocol in 147 hospitals in
14 countries. All patients gave a typical history of inter-
mittent claudication due to atherosclerosis, confirmed by
ankle/arm pressure ratio below 0.85 in both ankle arteries
of at least one leg. Patients who had fulfilled those criteria
in the past, but did not at the time of randomisation
because of a successful arterial reconstruction, were also
admitted to the study. The only important exclusion
criteria were patients on beta blockers or platelet active
drugs and patients with rest pain or gangrene. Following
randomisation all patients were monitored for the following
cardiovascular events for a minimum of 1 year; only four
patients were lost to follow-up. (1) Definite myocardial
infarction, fatal and non-fatal. (2) Definite major stroke,
fatal and non-fatal. (3) Major amputation above the ankle,
fatal and non-fatal. (4) Definite non-vascular death. (5)
Other deaths presumed to be vascular, apart from fatal
myocardial infarction, stroke or amputation, which were
included in events 1,2 and 3. (6) Deterioration of arterial
disease in a leg requiring surgical intervention or
angioplasty.
Detailed documentation of every possible event,
whether fatal or not, was reviewed by an international
validation committee, who frequently requested additional
data until a definite diagnosis could be made. All surviving
patients were followed for a minimum of a year with a total
follow-up of 2129 patient-years.
The data were analysed using the Cox proportional
hazards regression model. Univariate models were fitted for
each of the factors considered and multivariate models
were fitted using the forward and backward stepping
procedure of BMDP program P2L.4Anticoagulants 172 (9%)
Antidiabetics 201 (10%)
Diuretics 444 (23%)
Antihypertensives 256 (13%)
ECG
Normal 1051 (53%)
Myocardial infarction 203 (10%)
a Mean arterial pressure.
b Highest systolic blood pressure on the worse leg.
Table 2 Frequency of events in 1969 patients.
1 Definite myocardial infarction 36 (12 fatal)
2 Major stroke 27 (8 fatal)
3 Amputation above ankle 32 (1 fatal)
4 Non-vascular death 28
5 Other vascular death 43
6 Deterioration of arterial disease in legs
requiring intervention
111Results
The entry characteristics of the patients are shown in
Table 1. Table 2 shows the frequency of the various
cardiovascular events during the follow-up period. Some
patients had multiple events. (This explains the slight
discrepancies from the analogous table in the main publi-
cation1 which looked at trial end-points, that is the first
event for each patient.) In total 92 patients died during the
follow-up period, which was equivalent to an annual
mortality of 4.3%.
A major value of such a large longitudinal study is to
determine the features of a patient with established clau-
dication, which are markers for severe cardiovascular
complications. The entry characteristics were therefore
analysed individually (univariate analysis) and in combina-
tion (multivariate analysis) as a predictor of the following
three end-points, (a) All cause mortality. (b) All major
strokes and definite myocardial infarctions, fatal or non-
fatal, plus other presumed vascular deaths (events 1, 2 and
5 in Table 2). (c) Deterioration of leg ischaemia as evi-
denced by the need for an amputation, arterial recon-
struction or angioplasty (events 3 and 6 in Table 2).
The results of the univariate analysis are expressed as
relative hazards, that is the event rate with the risk factor
relative to the rate without the factor, and are shown in
Table 3. Apart from age, only a history of coronary disease
and an ankle/arm pressure ratio below 0.5 are significantpredictors of “All cause mortality” at a p value less than
0.01. The same three risk factors were significant in
a multivariate analysis at a level of pZ 0.05 or less. For all
vascular deaths plus non-fatal major stroke and definite
myocardial infarction the same three factors with the
addition of hypertension and diabetes were significant at
the same level. For “Deterioration of leg ischaemia” only
Table 3 Predictive value of various risk factorsdunivari-
ate analysis showing relative hazard and 95% confidence
limits.
All cause
mortality
Deterioration of
leg ischaemia
Age (per 10 year) 2.08 (1.61e2.68) 1.18 (0.97e1.42)
Ankle/arm pressure
ratio (0.5)
2.02 (1.27e3.24) 2.31 (1.57e3.40)
Coronary disease 2.03 (1.33e3.10) 1.27 (0.87e1.85)
Hypertension 1.77 (1.12e2.78) 0.98 (0.68e1.39)
Diabetes 1.67 (1.0e2.80) 1.30 (0.82e2.08)
Sex 1.29 (0.73e2.26) 1.66 (0.99e2.79)
C.V.A. 1.06 (0.51e2.23) 1,83 (1.10e3.04)
Smoking
(to 6 months ago)
0.80 (0.51e1.25) 1.40 (0.91e2.16)
Previous vascular
surgery
0.55 (0.34e0.90) 1.72 (1.21e2.44)
S6 J.A. Dormandy, G.D. Murraythe ankle/arm ratio and previous vascular surgery are
significant hazards at a p value less than 0.01 both in
univariate and multivariate analysis.
The haemoglobin concentration, haematocrit and
cholesterol at entry were also analysed but showed no
correlation with mortality or deterioration of leg ischaemia.
The initial white cell count however was a significant
predictor of myocardial infarction, stroke and vascular
mortality (pZ 0.05).
Discussion
In addition to some expected results, such as older patients
are more likely to die, there are some surprising positive
and negative findings in relation to mortality. Patients with
previous arterial surgery on the leg or smokers are not more
likely to die. By contrast, the ankle/arm pressure ratio
(below 0.5) is as good a predictor of total mortality or
cardiovascular events as a history of previous coronary
disease and a better predictor than diabetes, smoking,
hypertension or the plasma cholesterol level. It is less
surprising that the ankle/arm pressure ratio is the bestpredictor in terms of deterioration of leg ischaemia. A
much smaller but much longer Danish study of similar
patients also showed the ankle systolic blood pressure to be
a significant risk factor for mortality as well as deteriora-
tion in the leg circulation.5 The absence of a significant
predictive value for mortality of the classical risk factors
such as hypertension, diabetes, smoking or high plasma
cholesterol suggests that these primary risk factors for the
development and early progression of atherosclerosis are
not necessarily risk factors in the final stages of the disease.
The predictive value of the initial white cell count supports
the recently described significance of the leucocyte in
ischaemic disease.6 The significance of the ankle/arm
systolic pressure ratio is possibly simply a reflection of the
fact that the legs are the only territory affected by
atherosclerosis where the severity of the disease can be
accurately and easily quantified by a non-invasive method.
The findings may have implications for the treatment policy
of patients presenting with intermittent claudication.
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